Cargando...
Evaluating the Proportion of Treatment Effect Explained by a Continuous Surrogate Marker in Logistic or Probit Regression Models
Using surrogate endpoints in clinical trials is desirable for drug development because the trials can be shortened and therefore more cost-effective. Validating a surrogate for the clinical endpoint is critical in this context. One of the key steps in statistical validation of a surrogate for a sing...
Gardado en:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2010
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2890300/ https://ncbi.nlm.nih.gov/pubmed/20577652 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1198/sbr.2009.0070 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|